Table 1 Clinical characteristics

 Female

193

37%

1

1

1

 Male

328

63%

1.12 (0.83–1.50)

1.06 (0.72–1.54)

1.01 (0.79–1.30)

 18–45

126

24%

1

1

1

 46–55

114

22%

2.04 (1.26–3.31)

2.08 (1.09–3.94)

1.70 (1.15–2.51)

 56–65

189

36%

2.99 (1.94–4.61)

2.87 (1.62–5.08)

2.09 (1.47–2.93)

 66–72

92

18%

3.26 (1.97–5.40)

3.43 (1.81–6.52)

2.32 (1.54–3.50)

 Aggressive B cell

121

23%

1

1

1

 Transformed B cell

107

21%

0.80 (0.53–1.20)

0.66 (0.40–1.09)

1.02 (0.72–1.46)

 Indolent B cell

49

9%

0.88 (0.56–1.40)

0.59 (0.32–1.10)

1.15 (0.76–1.74)

 Mantle cell

99

19%

0.50 (0.32–0.78)

0.38 (0.21–0.66)

0.65 (0.45–0.95)

 T cell

85

16%

0.71 (0.47–1.10)

0.51 (0.29–0.90)

0.80 (0.55–1.18)

 Classical Hodgkin

60

12%

0.37 (0.21–0.66)

0.19 (0.08–0.49)

0.54 (0.33–0.87)

 Upfront

183

35%

1

1

1

 Relapsed disease

249

48%

1.85 (1.31–2.62)

1.82 (1.17–2.84)

1.50 (1.13–2.00)

 Refractory disease

88

17%

2.48 (1.64–3.73)

2.58 (1.53–4.36)

1.95 (1.37–2.77)

 1994–2004

112

21%

1

1

1

 2005–2014

239

46%

0.93 (0.67–1.29)

1.15 (0.74–1.77)

0.92 (0.58–1.23)

 2015–2019

170

33%

0.54 (0.34–0.87)

0.74 (0.41–1.33)

0.82 (0.57–1.19)

 1

201

41%

1

1

1

 2

256

52%

1.65 (1.19–2.29)

1.80 (1.18–2.76)

1.44 (1.09–1.89)

 3 or more

37

7%

2.32 (1.33–4.07)

2.70 (1.36–5.39)

1.81 (1.11–2.96)

 BEAM

497

95%

1

1

1

 BEAC

20

4%

1.22 (0.57–2.61)

1.57 (0.69–3.59)

1.59 (0.88–2.84)

 BCNU-Thiotepa

3

1%

NA

NA

NA

 Cy-TBI

1

0%

NA

NA

NA

 No

63

17%

1

1

1

 Yes

313

83%

0.61 (0.42–0.87)

0.76 (0.47–1.22)

0.73 (0.53–1.02)